Targeted Therapy for Recurrent Ovarian Cancer Based on Signal Transduction Pathway Activity Using a New mRNA Test

What this Trial Is About

Researchers are evaluating a new approach for women with recurrent ovarian cancer using a novel mRNA-based test called Signal Transduction Activation STA analysis. This technique identifies the main active signal transduction pathway STP driving tumor growth to guide targeted therapy with existing drugs that have manageable side effects. The goal is to improve progression-free survival and maintain quality of life by matching therapy to each patients tumor biology. The study includes women with platinum-resistant recurrent ovarian cancer or those who are not yet eligible or who decline standard chemotherapy. After a biopsy of the recurrent tumor, STA analysis determines the dominant pathway. Patients with active estrogen receptor, androgen receptor, phosphoinositide 3-kinase, or Hedgehog pathways will receive corresponding targeted drugs such as Letrozole, Bicalutamide, Everolimus, or Itraconazole daily until disease progression. Treatment decisions are reviewed by a multidisciplinary tumor board. Participants will be monitored regularly with imaging every 12 weeks to assess tumor response and progression according to RECIST 1.1 criteria. Researchers will collect data on progression-free survival comparing current therapy to prior treatment, side effects, quality of life, and overall survival for up to 36 months. Additional evaluations include changes in pathway activity scores and health economics. The study runs up to 36 months with ongoing safety and treatment effect monitoring.

Signal TrAnsduction Pathway Activity Analysis in OVarian cancER